Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Clare Morgan
Observed names:
C Morgan,
C. Morgan,
Clare P. Morgan,
Morgan, Clare
Institution:
Royal College of Surgeons in Ireland
Observed institutions:
Queen's University Belfast,
Royal College of Surgeons in Ireland,
University of California, Los Angeles,
Trinity College Dublin,
Beaumont Hospital,
St. Vincent's University Hospital,
Dublin City University
show all 7
OpenAlex ID:
A5067904174
BCL-2 system analysis identifies high-risk colorectal cancer patients
2016
·
Andreas U Lindner
, Manuela Salvucci
, et al.
·
Gut
·
57
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
2014
·
N. Elster
, M. Cremona
, et al.
·
Breast Cancer Research and Treatment
·
52
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
2021
·
M. Janusz Mezynski
, Angela M. Farrelly
, et al.
·
Journal of Translational Medicine
·
48
PDF
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
2020
·
Alexandra Canonici
, Alacoque L. Browne
, et al.
·
Therapeutic Advances in Medical Oncology
·
38
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
2016
·
Manuela Salvucci
, Maximilian L. Würstle
, et al.
·
Clinical Cancer Research
·
27
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
2018
·
Ozlem Aslan
, Mattia Cremona
, et al.
·
BMC Cancer
·
25
PDF
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
2017
·
John O’Shea
, Mattia Cremona
, et al.
·
Oncotarget
·
25
PDF
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
2022
·
Mattia Cremona
, Cassandra J. Vandenberg
, et al.
·
British Journal of Cancer
·
18
PDF
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
2020
·
Sinead Toomey
, Aoife Carr
, et al.
·
Journal of Translational Medicine
·
18
PDF
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
2018
·
Malgorzata Milewska
, Mattia Cremona
, et al.
·
Therapeutic Advances in Medical Oncology
·
15
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
2018
·
Naomi Elster
, Sinead Toomey
, et al.
·
Therapeutic Advances in Medical Oncology
·
14
A Mutation-Independent Therapeutic Strategy for Dominant Dystrophic Epidermolysis Bullosa
2013
·
Clare P. Morgan
, Danny S.I. Allen
, et al.
·
Journal of Investigative Dermatology
·
11
Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer
2016
·
A. Canonici
, M.F.K. Ibrahim
, et al.
·
Annals of Oncology
·
4
PDF
Simulated eye clinic and virtual eye case: alternative worlds for medical students
2016
·
Michael Andrew Williams
, Catherine Ross
, et al.
·
BMJ Simulation & Technology Enhanced Learning
·
3
Abstract P4-03-15: Targeting Src kinase blocks development of afatinib resistance in HER2-positive breast cancer
2018
·
N Conlon
, A Canonici
, et al.
·
Cancer Research
·
1
Mechanisms of acquired afatinib resistance in HER2-positive breast cancer cells.
2015
·
Alexandra Canonici
, Neil Conlon
, et al.
·
Journal of Clinical Oncology
·
1
Additional file 1: Table S1. of Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
2018
·
Ozlem Aslan
, Cremona, Mattia
, et al.
·
Figshare
Additional file 3: Figure S1. of Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
2018
·
Ozlem Aslan
, Cremona, Mattia
, et al.
·
Figshare
Additional file 2: Table S2. of Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
2018
·
Ozlem Aslan
, Cremona, Mattia
, et al.
·
Figshare
Abstract LB-354: Investigating potential molecular biomarkers for cetuximab response in metastatic colorectal cancer tissue using reverse phase protein array
2016
·
Naser Monsefi
, Robert O’Byrne
, et al.
·
Cancer Research
Abstract 3269: Recapitulating the BETH adjuvant breast cancer trial (NCT00625898) using clinically accurate orthotopic surgical resection models
2016
·
Liam S. Shiels
, Ian S. Miller
, et al.
·
Cancer Research
Abstract 4924: Retrospective evaluation of a system model of the BCL2 family of proteins as a predictive and prognostic biomarker for the clinical outcome of stage II-IV colorectal cancer patients
2016
·
Andreas U. Lindner
, Manuela Salvucci
, et al.
·
Cancer Research
Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.
2016
·
Manuela Salvucci
, Maximilian Wuerstle
, et al.
·
Journal of Clinical Oncology
A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.
2016
·
Jochen Prehn
, Andreas Ulrich Lindner
, et al.
·
Journal of Clinical Oncology
Exploration of RNAi-based theraupeutic strategies for Dominant Dystrophic Epidermolysis Bullosa
2011
·
Clare Morgan
·
Arrow@dit (Dublin Institute of Technology)
Show more works
View as search
Works count:
37
Citation count:
357
H-index:
11
I10-index:
12
Year
Topic
Type